TEZAMPANEL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H21N5O2
Molecular Weight	279.3381
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1C[C@H]2C[C@@H](CCC3=NN=NN3)CC[C@H]2CN1

InChI

InChIKey=ZXFRFPSZAKNPQQ-YTWAJWBKSA-N

InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H21N5O2
Molecular Weight	279.3381
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15196302 | https://www.ncbi.nlm.nih.gov/pubmed/8609884

Tezampanel, also known as LY 293558 and NGX-424, is a drug originally developed by Eli Lilly, which is a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family. Tezampanel was in phase II clinical trial for treatment migraine, but this study was discontinued. Also this drug has several others potential pharmacological actions, one of them is anxiety disorders

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate receptor ionotropic kainate 24 Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8609884	Antagonist 2849
Glutamate receptor ionotropic AMPA 42 Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7760975	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15196302	Primary		Phase II 1147	Unknown Approved Use Unknown
Anxiety 275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16470401	Primary		Preclinical	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
18433 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954	15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		TEZAMPANEL plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
9396 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954	15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		TEZAMPANEL plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954	15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		TEZAMPANEL plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz.	2001 May 7	11354378
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.	2001 Oct	11668589
Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior.	2001 Sep	11522463
Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging.	2005 Aug	15864556
The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain.	2006 Oct	17018337
Gateways to clinical trials.	2008 Oct	19088949
Fractionating spatial memory with glutamate receptor subunit-knockout mice.	2009 Dec	19909269
Regulation of AMPA receptors in spinal nociception.	2010 Jan 21	20092646

Sample Use Guides

In Vivo Use Guide

Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg

Route of Administration: Other

In Vitro Use Guide

LY293558 (Tezampanel) had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:26 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:26 GMT 2025`
Record UNII	GA36S2O9C2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-293,558

Preferred Name

English

TEZAMPANEL

Official Name

English

NGX424

Code

English

3-ISOQUINOLINECARBOXYLIC ACID, DECAHYDRO-6-(2-(1H-TETRAZOL-5-YL)ETHYL)-, (3S,4AS,6R,8AS)-

Common Name

English

NGX-424

Code

English

(3S,4AS,6R,8AS)-6-(2-(1H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID

Common Name

English

LY-293558

Code

English

TEZAMPANEL [USAN]

Common Name

English

TEZAMPANEL ANHYDROUS

Common Name

English

tezampanel [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795